{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:05:22Z","timestamp":1792123522082,"version":"4.4.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    This study aimed to identify predictive factors for early and late responders to tralokinumab treatment. Early responders were defined as patients achieving investigator\u2019s global assessment (IGA) 0\/1 at week 12, whereas late responders were defined as those without IGA 0\/1 at week 12 but achieving IGA 0\/1 at week 24.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    A prospective study was conducted with 108 Japanese AD patients treated with tralokinumab between October 2023 and August 2024. Patients\u2019 background factors and baseline clinical or laboratory indexes were compared between responders and poor responders.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Both early and late responders had a higher proportion of systemic therapy-naive patients compared with poor responders. Early responders had higher proportion of females, younger age, shorter disease duration, lower body mass index, and monocyte-to-lymphocyte ratio, whereas late responders had lower immunoglobulin E, thymus and activation-regulated chemokine, platelet-to-lymphocyte ratio, and C-reactive protein compared with poor responders.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    This study provides valuable insights for optimizing treatment strategies in AD, in selecting patients who may respond to tralokinumab at early or late phases.\n                  <\/jats:p>","DOI":"10.1089\/derm.2024.0460","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:34:32Z","timestamp":1735299272000},"page":"500-508","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic, Funabashi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-2312","authenticated-orcid":false,"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.12.646"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.008"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16549"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.08.009"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100195"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000499431"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13160"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1858802"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0627"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00702-2"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20832"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad038"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0030"},{"key":"e_1_3_1_22_2","article-title":"An open-label prospective observational study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab","author":"Polaskey MT","year":"2024","unstructured":"Polaskey MT, , Fakhraie S, , Daftary K, et al. An open-label prospective observational study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab. Dermatitis. 2024; doi: 10.1089\/derm.2024.0084","journal-title":"Dermatitis"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0261"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179553"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0445"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12083046"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5701949"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17186"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062201"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13230"},{"key":"e_1_3_1_32_2","article-title":"Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study","author":"Hagino T","year":"2024","unstructured":"Hagino T, , Onda M, , Saeki H, et al. Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study. Dermatitis. 2024; doi: 10.1089\/derm.2024.0323","journal-title":"Dermatitis"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2310643"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.01.015"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15957"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.1062412"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.070"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.002"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.052"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2024.0460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:15:31Z","timestamp":1789809331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/derm.2024.0460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["10.1089\/derm.2024.0460"],"URL":"https:\/\/doi.org\/10.1089\/derm.2024.0460","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}